

Date: January 11, 2023

Administrative Circular: 2023:01

ATTN: Medical Health Officers and Branch Offices Public Health Nursing Administrators and Assistant Administrators Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- Revised age indication for the primary series of Novavax from 18 years of age and older to 12 years of age and older per Health Canada authorization.
- Hyperlinks to respective COVID-19 vaccine product pages have been added.

Please remove page numbers: 1-3 dated December 9, 2022 Please add new page numbers: 1-3 dated January 2023

COVID-19 Vaccine NUVAXOVID™ (Novavax)

- INDICATIONS: Revised age indication from 18 years of age and older to 12 years of age and older per Health Canada authorization.
- DOSES AND SCHEDULES: Content from BOOSTER DOSE section has been moved to DOSES AND SCHEDULES section.
- ADVERSE EVENTS: Content added indicating pericarditis and myocarditis in association with Novavax COVID-19 vaccine have been reported internationally, with no reports in Canada per <u>Public Health Agency of Canada reports</u> to Dec. 9, 2022. A longer interval of 8 weeks between doses of the primary series may reduce the likelihood of pericarditis and myocarditis, particularly for males 12-39 years of age.

Please remove page numbers: 1-3 dated November 4, 2022 Please add new page numbers: 1-3 dated January 2023





Page 1 of 3

BC Centre for Disease Control Provincial Health Services Authority

Mpox Vaccine

Smallpox and Mpox Vaccine (Live attenuated, non-replicating): IMVAMUNE®

Per <u>World Health Organization recommendations</u> the term 'Monkeypox' has been replaced with the preferred term 'Mpox.'

Please remove page numbers: 1-4 dated November 4, 2022 Please add new page numbers: 1-4 dated January 2023

The client information sheet for recipients of mpox vaccine has been revised with the preferred term 'Mpox' and the title has been updated to "<u>Mpox (Monkeypox) Vaccine</u> <u>Client Information Sheet</u>".

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated December 2022, and replace with the enclosed updated Title Page and Table of Contents dated January 2023.





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: <u>stephanie.meier@bccdc.ca</u>).

Sincerely,

deitre brans

Monika Naus MD MHSc FRCPC FACPM Medical Director Immunization Programs and Vaccine Preventable Diseases Service BC Centre for Disease Control

pc:

Provincial Health Officer Dr. Bonnie Henry

BC Ministry of Health, Population & Public Health Division:

Brian Sagar Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong Executive Director, Public Health, Planning and Prevention, Population and Public Health Division



